Gold prices set for weekly drop as strong dollar weighs; Trump tariffs in focus
EDMONTON - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), a cannabis producer with annual revenue of $238.59 million and a market capitalization of $220.55 million, has expanded the eligibility criteria for its medical cannabis compassionate pricing program in Canada, increasing the yearly income threshold from $40,000 to $60,000 CAD for patients using AuroraMedical.com.
The expanded program aims to make medical cannabis more accessible to a broader range of patients. According to Geoff Hoover, SVP of Canadian Commercial at Aurora, "Over half of the country’s adult population fits within this income threshold." The company maintains strong financial health with a healthy gross profit margin of 54.65% and a current ratio of 4.31, indicating solid operational efficiency. (InvestingPro analysis reveals 8 additional key financial metrics for Aurora Cannabis.)
Alongside the pricing program update, Aurora has introduced new medical cannabis products including Aurora | Mediora Minis - Cannatonic CBD Flower, Daily Special | Sativa J’s THC Pre-Rolls, and WMMC | Seasonal Stash Petro Biscuit THC Flower.
The company also offers resources to specific groups including seniors, pediatric patients, veterans, and first responders seeking medical cannabis treatment.
Aurora Cannabis, headquartered in Edmonton, Alberta, serves both medical and consumer cannabis markets across Canada, Europe, Australia, and New Zealand. The company’s portfolio includes multiple brands targeting different market segments.
The information about the expanded pricing program was announced in a company press release statement.
In other recent news, Aurora Cannabis Inc. has filed its financial statements and management’s discussion and analysis for the fourth quarter and fiscal year ending March 31, 2025. The company also submitted a Form 6-K report to the U.S. Securities and Exchange Commission, detailing its activities for June 2025 as part of its routine disclosure obligations. Additionally, Aurora Cannabis has expanded its IndiMed brand in Australia by introducing two new high-potency medical cannabis strains, IndiMed TEMPO 22 | Lemon Laser and IndiMed TEMPO 22 | Pickled Petrol, through its subsidiary MedReleaf Australia. These products are designed to enhance treatment options for patients, featuring 22% THC content and less than 1% CBD. Aurora Cannabis has denied reports of an acquisition of New Zealand-based MedLeaf Therapeutics, clarifying that no discussions or agreements have taken place. The company’s recent activities underscore its strategy of international growth and innovation in the medical cannabis sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.